Company Overview
- Headquarters
- 777 W 41st St., Suite 401, Miami Beach FL
- Website
- sab.bio
- Phone
- (605) 679-6980
- Employees
- 70
- Industry
- Materials/Manufacturing
Financials & Stats
Revenue
$50B
Who is SAB Biotherapeutics
SAB Biotherapeutics is a clinical-stage biopharmaceutical company headquartered in Miami Beach, Florida. The company employs 70 people and generates approximately $50 million in annual revenue. SAB Biotherapeutics focuses on developing fully-human anti-thymocyte immunoglobulin (hIgG) as a novel immunotherapy platform. This platform is designed to delay the onset or progression of type 1 diabetes (T1D). The company's unique approach to immunotherapy utilizes hIgG, a type of antibody, to target and modulate the immune system's response in individuals with T1D. This targeted approach aims to prevent or slow down the autoimmune destruction of insulin-producing cells in the pancreas. For more information about SAB Biotherapeutics and its innovative therapies, please visit their website at sab.bio.
Company Leadership
Companies Similar to SAB Biotherapeutics
Analyze industry trends and opportunities by examining competitors and companies comparable to SAB Biotherapeutics, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 50M | 14 | Irving, TX | ||
| 50M | 66 | Woonsocket, RI | 1985 | |
| 50M | 70 | Wayne, PA | 2012 | |
| 50M | 11 | |||
| 50M | 8 | Boulder, CO | 1979 |